Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | LCK | P06239 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17021383 | 0.93 | JAK3 (0.52) | JAK3EPHX2EGFRLCKNAMPT | |
| SCHEMBL19010277 | 0.87 | KMT2A (0.44) | NAMPT | |
| SCHEMBL19010262 | 0.87 | JAK3 (0.51) | JAK3EPHX2EGFRLCKNAMPT | |
| SCHEMBL19010375 | 0.86 | JAK3 (0.56) | JAK3EPHX2EGFRLCKNAMPT | |
| SCHEMBL4402545 | 0.83 | JAK3 (0.68) | JAK3EGFRLCKBTKPTK2 | |
| SCHEMBL19010296 | 0.81 | STAT6 (0.44) | JAK3NAMPTKDM4E | |
| SCHEMBL17021283 | 0.80 | JAK3 (0.55) | JAK3EPHX2EGFRLCKNAMPT | |
| SCHEMBL17021296 | 0.80 | STAT6 (0.47) | JAK3NAMPTJAK2 | |
| SCHEMBL17021280 | 0.79 | JAK3 (0.61) | JAK3EPHX2EGFRLCKENPP2 | |
| SCHEMBL19010274 | 0.79 | GFER (0.49) | ENPP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK3 3/4885EPHX2 3287/4885EGFR 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.